Growth Rate Inhibition Metrics Correct for Confounders in Measuring Sensitivity to Cancer Drugs

Overview

Journal Nat Methods

Specialties Biomedical Engineering
Pathology

Date 2016 May 3

PMID 27135972

Citations 345

Authors

Marc Hafner

Mario Niepel

Mirra Chung

Peter K Sorger

Affiliations

Soon will be listed here.

Abstract

Drug sensitivity and resistance are conventionally quantified by IC50 or Emax values, but these metrics are highly sensitive to the number of divisions taking place over the course of a response assay. The dependency of IC50 and Emax on division rate creates artefactual correlations between genotype and drug sensitivity, while obscuring valuable biological insights and interfering with biomarker discovery. We derive alternative small molecule drug-response metrics that are insensitive to division number. These are based on estimation of the magnitude of drug-induced growth rate inhibition (GR) using endpoint or time-course assays. We show that GR50 and GRmax are superior to conventional metrics for assessing the effects of small molecule drugs in dividing cells. Moreover, adopting GR metrics requires only modest changes in experimental protocols. We expect GR metrics to improve the study of cell signaling and growth using small molecules and biologics and to facilitate the discovery of drug-response biomarkers and the identification of drugs effective against specific patient-derived tumor cells.

Citing Articles

Head and neck tumor organoid biobank for modelling individual responses to radiation therapy according to the TP53/HPV status.

Issing C, Menche C, Richter M, Mosa M, von der Grun J, Fleischmann M J Exp Clin Cancer Res. 2025; 44(1):85.

PMID: 40045309 PMC: 11881459. DOI: 10.1186/s13046-025-03345-3.

Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy.

Sanchez-Diez M, Romero-Jimenez P, Alegria-Aravena N, Gavira-ONeill C, Vicente-Garcia E, Quiroz-Troncoso J Pharmaceutics. 2025; 17(2).

PMID: 40006615 PMC: 11859577. DOI: 10.3390/pharmaceutics17020247.

Circadian clock features define novel subtypes among breast cancer cells and shape drug sensitivity.

Ector C, Didier J, De Landtsheer S, Nordentoft M, Schmal C, Keilholz U Mol Syst Biol. 2025; .

PMID: 39994450 DOI: 10.1038/s44320-025-00092-7.

Development of an ALK-positive Non-Small-Cell Lung Cancer in Vitro Tumor 3D Culture Model for Therapeutic Screening.

Berry M, Bland A, Major G, Ashton J J Histochem Cytochem. 2025; 73(1-2):63-79.

PMID: 39991927 PMC: 11851580. DOI: 10.1369/00221554251318435.

BESTDR: Bayesian quantification of mechanism-specific drug response in cell culture.

McDonald T, Bruno S, Roney J, Zervantonakis I, Michor F bioRxiv. 2025; .

PMID: 39975018 PMC: 11839102. DOI: 10.1101/2025.02.05.636681.

References

Haibe-Kains B, El-Hachem N, Birkbak N, Jin A, Beck A, Aerts H . Inconsistency in large pharmacogenomic studies. Nature. 2013; 504(7480):389-93. PMC: 4237165. DOI: 10.1038/nature12831. View

Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M . Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3):1630-9. DOI: 10.1158/0008-5472.CAN-05-1182. View

Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View

Shi J, Orth J, Mitchison T . Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 2008; 68(9):3269-76. DOI: 10.1158/0008-5472.CAN-07-6699. View

Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley D . Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012; 7(3):562-78. PMC: 3334321. DOI: 10.1038/nprot.2012.016. View

Rees M, Seashore-Ludlow B, Cheah J, Adams D, Price E, Gill S . Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2015; 12(2):109-16. PMC: 4718762. DOI: 10.1038/nchembio.1986. View

Moasser M, Basso A, Averbuch S, Rosen N . The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001; 61(19):7184-8. View

Baguley B, Marshall E, Whittaker J, Dotchin M, Nixon J, McCrystal M . Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer. 1995; 31A(2):230-7. DOI: 10.1016/0959-8049(94)00472-h. View

10.

Kim J, Kushiro K, Graham N, Asthagiri A . Tunable interplay between epidermal growth factor and cell-cell contact governs the spatial dynamics of epithelial growth. Proc Natl Acad Sci U S A. 2009; 106(27):11149-53. PMC: 2708686. DOI: 10.1073/pnas.0812651106. View

11.

Rouzier R, Perou C, Fraser Symmans W, Ibrahim N, Cristofanilli M, Anderson K . Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11(16):5678-85. DOI: 10.1158/1078-0432.CCR-04-2421. View

12.

Cravatt B, Gottesfeld J . Chemical biology meets biological chemistry minireview series. J Biol Chem. 2010; 285(15):11031-2. PMC: 2856974. DOI: 10.1074/jbc.R110.113126. View

13.

. Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015; 528(7580):84-7. PMC: 6343827. DOI: 10.1038/nature15736. View

14.

Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q . Revisiting inconsistency in large pharmacogenomic studies. F1000Res. 2017; 5:2333. PMC: 5580432. DOI: 10.12688/f1000research.9611.3. View

15.

Nam H, Benezra R . High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell. 2009; 5(5):515-26. PMC: 2775820. DOI: 10.1016/j.stem.2009.08.017. View

16.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

17.

OConnor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M . Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57(19):4285-300. View

18.

Yuan H, Myers S, Wang J, Zhou D, Woo J, Kallakury B . Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med. 2012; 367(13):1220-7. PMC: 4030597. DOI: 10.1056/NEJMoa1203055. View

19.

Dimanche-Boitrel M, Garrido C, Chauffert B . Kinetic resistance to anticancer agents. Cytotechnology. 1993; 12(1-3):347-56. DOI: 10.1007/BF00744672. View

20.

Fallahi-Sichani M, Honarnejad S, Heiser L, Gray J, Sorger P . Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol. 2013; 9(11):708-14. PMC: 3947796. DOI: 10.1038/nchembio.1337. View